Prof Enriqueta Felip (Vall d’Hebron Institute of Oncology, Barcelona, Spain), Prof Pascale Tomasini (Aix-Marseille University, Marseille, France), and Prof Nicolas Girard (Institut Curie, Paris, France) provide an expert overview of recent developments in the management of EGFR-mutated non-small cell lung cancer (NSCLC).

The discussion includes key updates from the phase 3 SACHI and HERTHENA-Lung02 studies, as well as the MARIPOSA-2 and COCOON trials.

Prof Girard highlights the efficacy of zipalertinib in patients with EGFR exon 20 insertion mutations previously treated with platinum-based chemotherapy, with or without amivantamab.

Prof Tomasini presents data on sacituzumab tirumotecan (sac-TMT) in patients with previously treated, advanced EGFR-mutated NSCLC.